84 participants
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-02
- Start Date:
- 2019-05-08
- Completion:
- 2027-02-01
Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Recurrent B Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
Interventions
- PROCEDURE
- BIOLOGICAL
- DRUG
No Results Yet